A groundbreaking study from the University of Plymouth has illuminated the potential of transcranial ultrasound stimulation (TUS), a non-invasive neuromodulation technique, to modulate the brain's response to pain. Researchers at the university's Brain Research and Imaging Centre (BRIC) demonstrated that targeted TUS to the dorsal anterior cingulate cortex (dACC)—a key region in the brain's pain network—can induce delayed but significant reductions in pain perception. This development positions UK higher education institutions at the forefront of innovative pain management research, offering hope for millions affected by chronic pain.

The research, published in the prestigious journal Nature Communications, involved 32 healthy participants who underwent double-blind sessions with either active or sham TUS while experiencing tonic cold pain stimuli. While no immediate analgesic effects were observed, participants reported markedly lower pain intensity ratings between 28 and 55 minutes post-stimulation compared to sham conditions. Functional magnetic resonance imaging (fMRI) and magnetic resonance spectroscopy (MRS) revealed altered sensory encoding, disrupted temperature-pain relationships, and enhanced functional connectivity between the dACC and regions like the supplementary motor area, premotor cortex, mid-anterior cingulate cortex, and supramarginal gyrus.

Decoding the Science: How TUS Targets the Brain's Pain Hub

The dACC serves as a critical hub in the brain's salience network, integrating sensory inputs with emotional and cognitive aspects of pain. Transcranial ultrasound stimulation employs low-intensity sound waves to precisely target deep brain structures without surgery or invasive implants, distinguishing it from techniques like transcranial magnetic stimulation (TMS), which struggle with depth penetration. In the Plymouth study, multi-focal TUS was delivered to three specific sites within the dACC using advanced k-Plan software from Brainbox, Inc., ensuring millimeter accuracy.

Step-by-step, the process unfolds as follows: participants' heads are positioned in a custom headset; ultrasound transducers emit focused waves monitored in real-time; concurrent neuroimaging captures biochemical shifts, such as glutamate levels via MRS; post-stimulation assessments track behavioral changes. This methodical approach not only validated TUS's safety but also its capacity to induce neuroplasticity, potentially reprogramming maladaptive pain circuits prevalent in chronic conditions.

University of Plymouth: Pioneering TUS in UK Academia

The University of Plymouth stands as a beacon in UK higher education for neuromodulation research, housing the nation's first Centre for Therapeutic Ultrasound (CENTUS) and BRIC. Established to advance TUS safety, biomechanics, and clinical applications, CENTUS integrates multidisciplinary expertise from neuroscientists, engineers, psychologists, and clinicians. Facilities include a state-of-the-art 3-Tesla MRI suite, hyperbaric chambers, and high-performance computing via Lovelace HPC, enabling sophisticated modeling of ultrasound-brain interactions.

BRIC's research spans neurotechnology, lifespan cognition, and brain health, with ongoing projects exploring TUS for anxiety, depression, addiction, Parkinson's, and OCD. Funded by £6.5 million from UK Research and Innovation (UKRI) and collaborations with NHS partners, these initiatives underscore Plymouth's commitment to translating academic discoveries into patient benefits.

Spotlight on Trailblazing Researchers

Dr. Sophie Clarke, lead author and Postdoctoral Research Fellow at Plymouth, brings expertise from her DPhil at Oxford on fMRI pain biomarkers and prior work at Exeter on virtual reality analgesia. Her current focus in Prof. Fouragnan's lab investigates TUS-pain interactions, stating, "Understanding these mechanisms will be very important to support the next steps in understanding whether the stimulation can be effective in helping patients with chronic pain."

Prof. Elsa Fouragnan, UKRI Future Leaders Fellow and CENTUS/BRIC Director, transitioned from biomedical engineering to computational neuroscience at Glasgow and Oxford. A pioneer in TUS for decision-making and psychiatric disorders, she notes, "The findings... are really promising, and we are already building on it." Dr. Sam Hughes from Exeter complements the team, emphasizing network alterations.

Photo by Dylan McLeod on Unsplash

The Chronic Pain Crisis in the UK: A Higher Ed Research Imperative

Chronic pain afflicts approximately 28 million UK adults—43% of the population—costing the economy £51 billion annually in healthcare and lost productivity. Conditions like fibromyalgia, arthritis, and neuropathic pain post-cancer often resist conventional opioids due to tolerance and side effects. UK universities, including Plymouth, are pivotal in addressing this through innovative neuromodulation, aligning with national priorities like the NHS Long Term Plan.

Academic research fosters interdisciplinary training, producing experts for clinical translation. For instance, Plymouth's Neurmod+ network funding (EP/W035057/1) supports such endeavors, highlighting higher education's role in public health innovation.

TUS vs. Traditional Neuromodulation: Academic Perspectives

• Spatial Precision: TUS reaches 5-10mm deep, surpassing TMS's cortical limits.
• Non-Invasiveness: No coils or implants, ideal for outpatient settings.
• Multi-Focal Capability: Simultaneous targeting of dACC subregions, as in Plymouth's protocol.
• Safety Profile: Low-intensity parameters validated by ITRUSST standards.

UK studies at Oxford and Nottingham complement Plymouth's work, but CENTUS leads in TUS-pain integration.

From Lab to Clinic: Next Steps in Plymouth's Research Pipeline

Building on this proof-of-concept, Plymouth plans patient trials for fibromyalgia and neuropathic pain, leveraging £1.2m funding to probe brain-state dependencies. Collaborations with Exeter and NHS Trusts aim for device commercialization. Early-phase trials elsewhere, like SPIRE's DIADEM for chronic pain, validate the trajectory.Read the full study here.

Challenges include optimizing parameters for diverse pain phenotypes and scaling multi-site stimulation.

Career Opportunities in UK Neuroscience Higher Education

This study exemplifies burgeoning opportunities in UK academia. Plymouth advertises Postdoctoral Fellowships in Fouragnan's lab, focusing on TUS neuromodulation. Roles span lecturers in cognitive neuroscience, research associates, and TARAs. Nationally, jobs.ac.uk lists 89 neuroscience positions, from Reading's Professorship to Cambridge vacancies.

Skills in neuroimaging, computational modeling, and clinical trial design are prized, with UKRI fellowships accelerating careers.

Photo by sue hughes on Unsplash

Funding and Collaborations Driving UK TUS Innovation

Plymouth's efforts are bolstered by UKRI (MR/Y034368/1, BB/Y001494/1), EPSRC Neuromod+, and ARIA. International ties via ITRUSST ensure global standards. Exeter partnerships exemplify UK higher ed's collaborative ethos, fostering PhD training and knowledge exchange.

These investments not only advance science but also train the next generation, positioning UK universities as neuromodulation leaders.

Future Outlook: Transforming Pain Research in Higher Education

The Plymouth study heralds a paradigm shift, where TUS could complement pharmacological therapies, reducing opioid reliance. For UK academia, it signals growth in neuroscience programs, interdisciplinary centers, and translational research. As chronic pain burdens the NHS, university-led innovations promise equitable, accessible solutions, underscoring higher education's societal impact.